Woman

Bellabeat Unveils Next-Gen IVY Health Tracker for Women: A Leap Forward in Advanced Temperature Tracking and Wellness

Retrieved on: 
Tuesday, March 19, 2024
Research, Temperature, Health, Medicine, Frontiers Media, Menstrual cycle, IVY, Heart rate, Ovulation, Journal, Fertility, Pregnancy, Woman, Reproductive biology, Skin temperature, Machine learning, Menstruation, Map, Endocrinology, Birth control

San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.

Key Points: 
  • San Francisco, California--(Newsfile Corp. - March 19, 2024) - In its latest endeavor to revolutionize women's health technology, Bellabeat has launched the new IVY+ Health Tracker.
  • It is equipped with a sophisticated temperature tracking feature, marking a significant advancement in menstrual and fertility tracking.
  • In conjunction with the Bellabeat app, the IVY+ Health Tracker transforms biometric data into actionable wellness insights.
  • The combination of the IVY+ Health Tracker and the Bellabeat app creates a comprehensive health monitoring experience that extends beyond traditional tracking methods.

Inc.’s 2024 Female Founders list highlights why female founders are always a good bet

Retrieved on: 
Tuesday, April 9, 2024
BCG, Genomics, AngelList, Organization, Growth, Female, Environment, Rihanna, Research, University, Entrepreneurship, Private sector, Doctor of Philosophy, Biology, Woman, Male, STEM, Molecular biology, Femtech, UW, Hedera, Nursing

Elizabeth Ruzzo, CEO and founder of adyn, was recognized by Inc. in this year’s Female Founders list.

Key Points: 
  • Elizabeth Ruzzo, CEO and founder of adyn, was recognized by Inc. in this year’s Female Founders list.
  • The female founders on this year’s list are a testament to what triumph over adversity looks like.
  • “One thing I bet all founders on this list share is an abundance of grit and determination.
  • Despite years of evidence demonstrating that female founders are a good bet, the fundraising environment remains bleak.

Signati™ Medical Enrolls First Patient in Groundbreaking Sealed Vasectomy Procedure Trial

Retrieved on: 
Tuesday, April 9, 2024
Anxiety, Patient, Woman, SVP, Vasectomy, Medicine, Physician, IDE, Safety, Birth control

This significant reduction in procedure time holds immense promise for improving patient experience and potentially increasing vasectomy rates.

Key Points: 
  • This significant reduction in procedure time holds immense promise for improving patient experience and potentially increasing vasectomy rates.
  • Principal Investigator Dr. Matthew Mutter of LSU Medical Center commented on the first patient enrollment: "The Signati Separo™ worked flawlessly.
  • The Sealed Vasectomy Procedure (SVP)™ represents the first major advancement in vasectomy technology in over 40 years.
  • The SVP is a minimally invasive, procedure that offers several potential benefits over traditional vasectomy techniques, including:
    The IDE trial is a prospective study designed to evaluate the safety and efficacy of the Signati Separo™ for vasectomy.

Ozop Energy Solutions, Inc. Continues to Grow its Advisory Board for OZOP ARC

Retrieved on: 
Tuesday, April 9, 2024
Arizona State University, NLB, Woman, American Institute of Architects, International, National Council, Certification, Social justice, American Institute, Lighting, ARC, WILD, Management

Warwick, NY, April 09, 2024 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OZSC), a pioneer in the field of innovative energy and lighting solutions, is delighted to announce the appointment of Alessa Aguayo as the newest member of the advisory board for its flagship OZOP ARC lighting controls system. The advisory board aims to utilize the expertise of seasoned industry professionals to propel the development and strategic positioning of OZOP ARC.

Key Points: 
  • The advisory board aims to utilize the expertise of seasoned industry professionals to propel the development and strategic positioning of OZOP ARC.
  • Alessa Aguayo brings a rich background in the lighting industry, with over a decade of experience spanning national accounts, distribution, and manufacturing.
  • Brian Conway, CEO of Ozop Energy Solutions, commented, “We are thrilled to welcome Alessa Aguayo to our advisory board.
  • With the addition of Alessa Aguayo, the board is poised to significantly impact the strategic trajectory of the OZOP ARC system.

Runway Growth Finance Corp. Provides First Quarter 2024 Portfolio Update

Retrieved on: 
Tuesday, April 9, 2024
Completion, Communication, Environment, Human, FiscalNote, Woman, Credit, Investment, Partial, Madison Reed, ETR

MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the first quarter ended March 31, 2024.

Key Points: 
  • MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the first quarter ended March 31, 2024.
  • The team is in a strong position to drive performance with ample capital to execute against our long-term growth strategy and deliver shareholder value.”
    In the first quarter of 2024, Runway Growth funded two investments: one investment in a new portfolio company and one investment in an existing portfolio company.
  • During the first quarter ended March 31, 2024, Runway Growth experienced two prepayments totaling $34.5 million and scheduled principal amortization of $0.4 million.
  • As of March 31, 2024, the Runway Growth portfolio included 47 debt investments to 30 portfolio companies and 80 equity investments in 49 portfolio companies, including 26 portfolio companies where Runway Growth holds both a debt and equity investment.

Lily AI’s Co-Founders Purva Gupta and Sowmiya Chocka Narayanan Make Inc.’s 2024 Female Founders List

Retrieved on: 
Tuesday, April 9, 2024
Gems, Organization, Female, Lilium, Box, Rihanna, Emotional intelligence, Food, Computer engineering, Texas Instruments, Shoe, University, Woman, Yahoo!, Gupta

“Thank you to Inc. for this incredible honor,” said Gupta, Lily AI’s Chief Executive Officer.

Key Points: 
  • “Thank you to Inc. for this incredible honor,” said Gupta, Lily AI’s Chief Executive Officer.
  • “This list is a true testament to the power female entrepreneurs have to change the world for the better.”
    “We are so proud to be included in Inc.’s 2024 Female Founders list,” said Chocka Narayanan, Chief Technology Officer, Lily AI.
  • The female founders on this year’s list are a testament to what triumph over adversity looks like.
  • Inc. magazine’s Female Founders issue (April 2024) will be available online on April 9 at https://www.inc.com/magazine and on newsstands on April 16.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
Tuesday, April 9, 2024
Plasma, MRI, Neoplasm, Atossa, Ki-67, Associate, RECIST, Magnetic resonance imaging, Incidence, Patient, MD, Woman, AACR, Clinical trial, Therapy, Breast cancer, Safety, Division, Recurrence, Exemestane, Annual general meeting, Medical imaging

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

Retrieved on: 
Tuesday, April 9, 2024
Elevance Health, Anthem, Gynaecology, Risk assessment, Medicare, Woman, Medicare Advantage, Physician, Health insurance

Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.

Key Points: 
  • Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.
  • “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite portfolio, which provides a clear benefit to physicians in their clinical assessment of women with adnexal masses,” said Torsten Hombeck, Chief Financial Officer of Aspira.
  • Our strategic focus on payer adoption continues to gather momentum.”
    Anthem is a leading health company dedicated to improving lives and communities.
  • Through its affiliated companies, Anthem serves more than 118 million people, including more than 45 million within its family of health plans.

Identity & Access Forum Spring Market Snapshot: Mobile Driver’s Licenses, Biometrics and Access Management Innovation

Retrieved on: 
Tuesday, April 9, 2024
Mastercard, Facial recognition, Counterfeit, Organization, Government, Ecosystem, Growth, Apple, DHS, Education, Patient, Travel, Research, Forum, DSCSA, Identity, NIST, Woman, Statistics, Generation Z, Fraud, String interpolation, RIV, Interest, Access, ID, IDS, Arizona Department, TSA, Gen, Android, Map, Online shopping

The future of identity and authentication is digital and mobile driver’s licenses are the next step in identity credentialing.

Key Points: 
  • The future of identity and authentication is digital and mobile driver’s licenses are the next step in identity credentialing.
  • Eric Jorgensen, director of the Arizona Department of Transportation’s Motor Vehicle Division, shared this sentiment while delivering the Identity and Access Forum Meeting’s keynote address.
  • The Identity and Access Forum’s primary focus is to provide a platform for solving cross-industry challenges and promoting innovation.
  • By joining the Secure Technology Alliance, members will have access to activities within the U.S. Payments Forum and the Identity and Access Forum and additional Alliance working committees.

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
Monday, April 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.